EMC.V - Emblem Corp.

TSXV - TSXV Delayed Price. Currency in CAD
1.0300
-0.0100 (-0.96%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0700
Bid1.02 x 0
Ask1.05 x 0
Day's Range1.0250 - 1.1000
52 Week Range0.8300 - 2.7600
Volume353,637
Avg. Volume797,215
Market Cap127.314M
Beta (3Y Monthly)9.36
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.05
  • GlobeNewswire3 days ago

    Emblem launches new line of Oil Capsules

    Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), through its wholly-owned subsidiary Emblem Cannabis Corporation, today announced the launch of a new line of 10mg Emblem Oil Capsules, providing its growing list of 6,000+ patients with a pre-dosed treatment format. The 10mg Emblem Oil Capsules offer a consistent patient experience formulated with three chemovar specific formats - High THC (10mg THC per capsule), High CBD (10 mg CBD per capsule) and Balanced (6mg THC/10 mg CBD per capsule).

  • GlobeNewswire23 days ago

    Emblem Corp. Reports Strong Third Quarter 2018 Financial Results

    Revenues increase 281% over the quarter ended September 30, 2017 and 50% over Q2 2018 TORONTO, Nov. 20, 2018 -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the.

  • ACCESSWIRE27 days ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire29 days ago

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis.  Their unique products offer advantages to the medical community, patients, adult use consumers and governments.  Canntab is pleased to provide this corporate update to its shareholders. A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.

  • GlobeNewswirelast month

    Emblem Corp. announces new board appointments

    Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) today announced the appointment of Connie A. Stefankiewicz and Loreto Grimaldi to its Board of Directors (the “Board”) following Emblem’s annual and special shareholders’ meeting. Harvey Shapiro, current chair, and Maxim Zavet have stepped down from the Board, and the Board would like to thank them for their immense contributions since Emblem’s inception. Ms. Stefankiewicz and Mr. Grimaldi will join current Board members Daniel Milliard, Jeffrey Fineberg, John H. Stewart, Terry Johnson and Nick Dean.

  • Simply Wall St.last month

    Is Emblem Corp (CVE:EMC) A Financially Sound Company?

    While small-cap stocks, such as Emblem Corp (CVE:EMC) with its market cap of CA$151m, are popular for their explosive growth, investors should also be aware of their balance sheet to Read More...

  • GlobeNewswire2 months ago

    Emblem finalizes agreement to launch Emblem Germany in joint venture with Acnos Pharma

    TORONTO, Oct. 24, 2018 (GLOBE NEWSWIRE) --  Emblem Corp.  (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company"), today announced that, through its wholly-owned subsidiary Emblem Cannabis Corporation (“ECC”), it has signed a definitive agreement with German pharmaceutical wholesaler Acnos Pharma GmbH (“Acnos”) in respect to launching a joint venture under the name “Emblem Germany” (the “JV”) for the purpose of exporting Emblem-branded cannabis products from Canada into Germany. The JV – owned 60% by ECC and 40% owned by Acnos – will allow Emblem to commence exporting its products to Germany, with first deliveries expected to be made in mid-2019.

  • VIDEO + B-ROLL: Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalization
    CNW Group2 months ago

    VIDEO + B-ROLL: Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalization

    VIDEO + B-ROLL: Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalization

  • ACCESSWIRE2 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Emblem Establishes Temporary "Patient Access Investment Fund" to Partially Cover Medical Cannabis Excise Tax
    CNW Group2 months ago

    Emblem Establishes Temporary "Patient Access Investment Fund" to Partially Cover Medical Cannabis Excise Tax

    TORONTO , Oct. 15, 2018 /CNW/ - Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company") today announced that it will segregate CDN $5 million of its current cash holdings to establish what it is calling the Patient Access Investment Fund (the "Fund"), the interest from which will be used to help offset some of the cost of the excise tax that will be applied to medical cannabis products, effective October 17, 2018 . On October 17 , the Access to Cannabis for Medical Purposes Regulations ("ACMPR") will be replaced by the Cannabis Act, and all Licensed Producers will be required to collect and submit a federal cannabis excise tax to the government. The standard rate tax is the greater of $1.00 /gram equivalent or 10% of the purchase price, with some provinces requiring an additional excise duty adjustment on top, which can range as high as 19.3% (the "New Excise Tax").

  • GlobeNewswire2 months ago

    Emblem Establishes Temporary “Patient Access Investment Fund” to Partially Cover Medical Cannabis Excise Tax

    Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company") today announced that it will segregate CDN $5 million of its current cash holdings to establish what it is calling the Patient Access Investment Fund (the “Fund”), the interest from which will be used to help offset some of the cost of the excise tax that will be applied to medical cannabis products, effective October 17, 2018. On October 17, the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) will be replaced by the Cannabis Act, and all Licensed Producers will be required to collect and submit a federal cannabis excise tax to the government. The standard rate tax is the greater of $1.00/gram equivalent or 10% of the purchase price, with some provinces requiring an additional excise duty adjustment on top, which can range as high as 19.3% (the “New Excise Tax”).

  • GlobeNewswire2 months ago

    A Letter from Emblem’s President & CEO

    Emblem continues to bring innovative products to market, most recently with the launch of Atmosphere oral sprays, and we’re firmly executing on our three-year strategy. Most notably, in the third quarter we executed a strategic pivot in our approach to cannabis production, cancelling our capital-intensive production plans, and instead electing to take advantage of the significant wholesale supply capacity coming online industry-wide. In practical terms this gives Emblem access to ample capacity, while freeing up our capital resources to focus on our passion for innovative value-added products where we already realize higher margin profiles.

  • GlobeNewswire2 months ago

    Emblem to supply British Columbia and Saskatchewan markets with high quality cannabis

    Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) (“Emblem” or the "Company") today announced that its wholly-owned subsidiary, Emblem Cannabis Corporation, one of Canada’s leading licensed producers of medical cannabis, has received approval to supply British Columbia and Saskatchewan with premium cannabis products under Emblem’s adult-use brand, Symbl. In B.C., Emblem has been approved to supply cannabis to the BC Liquor Distribution Branch (“BCLDB”) – the sole, wholesale distributor of non-medical cannabis for the province that will operate standalone, public retail stores and provide online sales. In Saskatchewan, Emblem has been approved by the Saskatchewan Liquor and Gaming Authority (“SLGA”) to supply cannabis to the province’s private retail market.

  • GlobeNewswire2 months ago

    Emblem Bolsters Medical Division to Support Growth and Product Innovation with Appointment of Wayne Kreppner as President

    Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company") today announced additional leadership and operational resources to support the rapid growth of its medical division and associated new product innovations. Mr. Stewart will oversee the Division in an advisory capacity and will remain a member of Emblem’s Board of Directors.

  • GlobeNewswire3 months ago

    Emblem Corp. Announces Grant of Stock Options

    Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) announced that the board of directors of the Company has approved the granting of 350,000 incentive stock options (the “Options”) to certain officers of the Company.  The Options are exercisable at a price of $1.60 per share for a period of five years and are subject to vesting as to one-third the number of Options granted on each of September 25, 2019, 2020 and 2021. Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations. Emblem is also the ultimate parent company of GrowWise Health Ltd., one of Canada’s leading medical cannabis education services.

  • GlobeNewswire3 months ago

    Emblem partners with DriveABLE to support research that evaluates impairment risk

    Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) today announced it has completed an equity investment in DriveABLE Assessment Centres Inc. (“DriveABLE”), a global leader in cognitive-based driving evaluations that measure the risk of impairment. Through this investment – to Emblem’s knowledge, the first of its kind in the cannabis space – Emblem will support DriveABLE as it seeks to tackle the issue of impairment on roads and in the workplace with new mobile technology. Using the knowledge gained from almost two decades of evaluating real world impairment risk in partnership with law enforcement agencies, universities and other industries that operate in safety-sensitive environments, DriveABLE is now developing a mobile cognitive evaluation tool that will focus on the risks associated with impairment.

  • ACCESSWIRE3 months ago

    3 Pot Stocks On The Move After Latest Industry News

    CORAL GABLES, FL / ACCESSWIRE / September 18, 2018 / Cannabis and marijuana stocks are striking up conversation in the market. The looming date in mid October has a number of investors speculating on what is to come for the cannabis industry once Canada is legally selling recreational marijuana across the country. Further to this, a larger cannabis company and one that has recently gone public in the US, Tilray (TLRY) will be "breaking down barriers" and importing medical cannabis into the US.A number of marijuana stocks are heading higher this month and include GTEC Holdings (GGTTF) (GTEC), Emblem Corp. (EMMBF) (EMC.V), and Green Thumb Industries (GTBIF)(TSX:GTII).

  • Newsfile3 months ago

    Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem"). Dissolution testing conducted by ...

  • GlobeNewswire3 months ago

    Emblem and Natura Naturals announce termination of letter of intent

    Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) through its wholly-owned subsidiary Emblem Cannabis Corporation, a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), and Natura Naturals Holdings Inc. (“Natura”) announced the termination of their letter of intent as of 5 p.m. EST on September 13, 2018. In addition, as previously announced, Emblem recently provided $2 million of advanced funding to Natura for the expansion of its facility (the “Funding”). The Funding is comprised of a one-year convertible debenture for an aggregate principal amount of up to $2 million, with an interest rate similar to Natura’s other funding obligations and can be pre-paid at any time during the term.

  • Global Cannabis Partnership Welcomes New Members
    CNW Group3 months ago

    Global Cannabis Partnership Welcomes New Members

    SAINT JOHN, NB , Sept. 13, 2018 /CNW/ - Momentum continues to build for the establishment of a Responsible Cannabis Framework as eight more organizations join the Global Cannabis Partnership (GCP), in its newly opened Member category. "We expect membership to expand as more and more stakeholders recognize the necessity of social responsibility policies and programs and want to be at the table to collaborate," says Kim Wilson , Executive Director of the GCP.

  • Global Cannabis Partnership Welcomes New Members
    PR Newswire3 months ago

    Global Cannabis Partnership Welcomes New Members

    SAINT JOHN, NB, Sept. 13, 2018 /PRNewswire/ - Momentum continues to build for the establishment of a Responsible Cannabis Framework as eight more organizations join the Global Cannabis Partnership (GCP), in its newly opened Member category. "We expect membership to expand as more and more stakeholders recognize the necessity of social responsibility policies and programs and want to be at the table to collaborate," says Kim Wilson, Executive Director of the GCP.

  • ACCESSWIRE3 months ago

    3 Marijuana Stocks in the News this Week

    CORAL GABLES, FL / ACCESSWIRE / September 13, 2018 / Marijuana stocks have come a long way especially since 2014 when Colorado first brought the idea of legal recreation cannabis sales to the forefront. Fast-forwarding to today and we are just over a month away from an entire country "flipping the switch" for legal recreational marijuana sales. In fact, data has emerged estimating that the legal cannabis industry will reach $146.4 billion by 2025, according to Grand View Research.

  • ACCESSWIRE3 months ago

    3 Pot Stocks Investors are Watching on Wednesday

    There a more licensed producers hitting the public markets all hoping to get a piece of the expanding Canadian marijuana industry. Mid October is when the country will go fully legal for recreational cannabis sales and further open the door for international trade. With this in mind, a number of marijuana stocks are heading higher this month and include GTECHoldings (GGTTF) (GTEC), Emblem Corp. (EMMBF) (EMC), and Green Thumb Industries (GTBIF)(GTII).